O'Loughlin Steve 4
4 · Actinium Pharmaceuticals, Inc. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−8,833→ 0 totalExercise: $23.49Exp: 2028-07-13→ Common Stock (8,833 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−1,666→ 0 totalExercise: $59.70Exp: 2026-04-14→ Common Stock (1,666 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−13,333→ 0 totalExercise: $6.96Exp: 2029-07-12→ Common Stock (13,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−256,438→ 0 totalExercise: $4.96Exp: 2032-07-01→ Common Stock (256,438 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−3,333→ 0 totalExercise: $53.70Exp: 2025-10-01→ Common Stock (3,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−253,123→ 0 totalExercise: $5.00Exp: 2033-12-28→ Common Stock (253,123 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−3,333→ 0 totalExercise: $41.70Exp: 2027-03-14→ Common Stock (3,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−59,066→ 0 totalExercise: $9.55Exp: 2030-08-12→ Common Stock (59,066 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−107,463→ 0 totalExercise: $6.07Exp: 2031-09-01→ Common Stock (107,463 underlying)
Footnotes (1)
- [F1]Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration.